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Abstract:
Aim: To assess the efficacy of scaffold mediated localized chemotherapy in cancer. 
Materials and Methods: PubMed, Cochrane Library, and SCOPUS databses were searched 
for articles reporting the use of scaffold mediated localized drug delivery in cancer.  Essential 
data including scaffold fabrication material and methods, the drug dosage and release 
duration, its effect on the cancer cells were extracted. 
Results: 15 articles out of 60 screened, fulfilled the eligibility criteria. Among the 15 studies, 5 
studies included only cell lines and 2 studies were only on mouse models while 8 studies 
involved a combination of cell lines and mouse models. The scaffold materials ranged from 
synthetic polymers such as poly-lactide, polycaprolactone, etc to natural scaffolds including d-
periosteum, human micro-fragmented adipose tissue, etc. 
Conclusion: Studies differed with respect to a wide number of variables ranging from the type 
of scaffold material used, the fabrication procedure, the nature of the drug used, and the tools 
used to assess the effect of the scaffold mediated drug on cancer. Due to these variables, it 
was not possible to make any direct comparison of the efficacy of therapeutic strategy used in 
each of these studies. Irrespective of the differences, a common consensus in all the included 
studies was that scaffold mediated localized drug delivery effectively reduced the cancer cell 
viability by increasing the bioavailability of the drug to the target tissue, while its localized effect 
reduces the risk of systemic toxicity.  
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In-vitro cell line and in-
vivo mouse model study




Mouse with SCC-9 cancer was divided into 4 groups:
Group 1: no treatment
Group 2: implanted scaffolds without diclofenac
Group 3: implanted scaffolds loaded with diclofenac
Group 4: diclofenac was given orally
Drug release duration: 7 weeks
Drug dosage released: 219.8±18.5 (in-vivo);  234.6±17.7 (in-vitro)/or 
77.5% (in vivo); 82.7% (in vitro)
7-week survival rate: Group 1- 25%; Group 2- 10%; Group 3- 89%; Group 4- 10%
Group 3 recurrence tumor weight was * lower than other groups
Ki-67 immunostaining was * lower in group 3 than other groups
Caspase 3 immunostaining was the same in all groups
Group 3 showed * greater survival rate and tumor inhibition than other groups/ 
The limitation was that the in vitro drug release was higher than in-vivo which in 




In-vitro cell line 
Scaffold: Bacterial (natural) Cellulose-Alginate (BC-Alg)
Drug: Doxorubicin (Dox)
Cell Lines: H29 Human colorectal adenocarcinoma
Group 1: Soluble free drug in µM (100,150,200)
Group 2: Scaffold without drug
Group 3: Scaffold with drug 9.55±1.87µmol/gm
Group 4: Scaffolds with drug 42.25±3.15 µmol/gm
Drug release duration: 48 hrs max.
Drug dosage released: Group 3: 76±5(24hr), 169±5(48hr)
Group 4: 77±5(24hr), 181.0±8(48hr)
Cell Viability % at 24 and 48 hrs
Group 2: 103±3.1 and 97.4±2.1
Group 3: 59±7.2 and 55±8.2
Group 4: 53±1.6 and 37±0.5
Anti-cancer effect with Dox loaded into BC-Alg films was more prominent than 
free drug. BC-Alg formulation, drug loading quantities and release kinetic 
conditions can modulate cytotoxic effect of Dox.
3. Chuan Chen/2018/China In-vitro cell line
Scaffold: D – periosteum (natural)
Drug: Adriamycin (ADM)
Cell Lines: Human Osteosarcoma Cells (HOSs)
Group 1: Control group (medium alone)
Group 2: adriamycin free drug
Group 3: adriamycin gelatin microspheres (ADM‐GMS)
Group 4: ADM-GMS D‐periosteum 
Group 5: adriamycin poly (dl‐lactide‐coglycolide) gelatin 
microspheres (ADM‐PLGA‐GMS)
Group 6: ADM‐PLGA‐GMS- D‐periosteum
Group 7: GMS-D Periosteum
Drug release duration: Maximum of 10 hrs
Drug dosage released: Group 2: Released within 1 hr
Group 3: Cumulative release of 80% within 10hr
Group 4:  Cumulative release within 10hr approx. same as group 3
Group 5: the cumulative release of 80% in 48 hrs
Group 6: the cumulative release of 76.6% in 48 hrs
The CCK‐8 cell counting test Group 2:  more HOSs were killed in 2hr and 12hr, with the inhibition rate of 42%, which 
was higher than those in other groups
At 24hr, Group 5 and 6 showed a higher rate of inhibition than other groups
Groups 3 and 4 Vs Groups 5 and 6 showed similar cell inhibition rates, respectively at all three-time points
D‐periosteum scaffold crosslinked with drug‐loaded microspheres showed high 
porosity slow release of ADM inhibiting HOS cancer cells. 
Future osteosarcoma animal model studies will be required to investigate  the 
potential of drug-loaded D‐periosteum against osteosarcoma and supporting 




In vitro Cell Lines
Scaffold: Poly(caprolactone)–poly(ethylene glycol) 
(PCL/PEG) (Electrospinning) 
Drug: 17-dimethylaminoethylamino-17-demethoxy 
geldanamycin (17-DMAG)/ Cell Lines: A549 lung cancer 
cells
Group 1: untreated cells
Group 2: Cells treated with free drug
Group 3: Cells treated with blank scaffolds
Group 4: Cells treated with drug-loaded scaffolds
Drug release duration: 7 hrs max.
Drug dosage released: 50 – 95% drug is released from 2-6 hrs
96% of the drug was released in 7 hrs
Expression of HSP90 mRNA
Group 2: expression levels reduced to about 13, 32, and 48% after 24, 48 and 72h, respectively 
Group 4: Expression levels reduced to about 39, 57, and 79% after 24, 48 and 72h, respectively
Telomerase activity
Group 2: The activity was reduced to 31, 51, and 71% after 24, 48 and 72h, respectively. 
Group 4: Reduced telomerase activity of the cells to about 54, 66, and 83% after 24, 48 and 72h, respectively.
17-DMAG-loaded PCL/PEG nanofibers had more inhibitory effect on cell 
proliferation, HSP90 mRNA expression, and telomerase activity than free 17-
DMAG. 
Drug-loaded scaffolds can be used for local drug administration and prevention of 




In vitro cell lines and in-
vivo mouse model
Scaffold: Acetalated dextran (Ace-DEX), polyester, 
poly(L-lactide) (PLA) Dissolution
Drug: doxorubicin (DXR)
Cell Lines: Human glioma cell lines U87-MG, LN-18, and 
LN-229
Group 1: No treatment





Drug release duration: 35 days max.
Drug dosage released: Ace-DEX/10DXR and PLA/10DXR  released 
similar amounts of DXR (approximately 50%) over 35 days
Steady-state release from Ace-DEX scaffolds is faster than that from 
PLA, which releases the 
majority of the DXR within the first 24 hours
Survival rate: Ace-DEX/10DXR statistically better compared to 
Ace-DEX/blank (p < 0.005) and ‘no treatment’
PLA/10DXR statistically better
compared to ‘no treatment’ control group (p < 0.05), but was not significant compared to 
PLA/blank
Progression-free survival rates: Ace-DEX/10DXR statistically better compared to Ace-DEX/blank (p < 0.01) and ‘no 
treatment’
PLA/10DXR statistically better 
compared to ‘no treatment’
Both PLA/10DXR and DXR loaded scaffolds showed sustained release of DXR over 
same period of time.
Higher and sustained amount of DXR release from Ace-DEX scaffolds led to higher 
suppression of tumor recurrence and complete remission in 43% of mice.
6. Ziming Yuan/2016/China
In vitro cell lines and in 
vivo female mice model
Scaffold: poly (L-lactide) (PLLA) fibrous scaffolds blent 
Electrospinning




Group 2: P-F (Blank)
Group 3: P-D-F
Group 4: P-M/D-F
Group 5: P-M/D-S-F (with sodium bicarbonate)
Drug release duration: 100 days
Drug dosage released: Lower initial burst and longer release time of P-
M/D-F and 
P-M/D-S-F compared with P-D-F at neutral pH
In-vitro anti-tumor activity:
P-M/D-S-F group had the strongest inhibition on tumor cells
Residual tumor tissues: Necrosis of P-M/D-S-F was very remarkable 
among all the groups
Expression of Bcl-2 and Bax:
P-M/D-S-F showed higher levels of Bax  and lower levels of Bcl-2 compared to all other groups
Expression of TNF-α and caspase-3: P-M/D-S-F showed highest levels of TNF-α and caspase-3
P-M/D-S-F can kill the post-surgical residual cancer cells as evidenced by reduced 
expression of Bcl-2 and TNF-α and a increased expression of Bax and caspase-3.
7. Qiuxia Ding/2015/China
In-vitro cell lines and  in-
vivo mice model study
Scaffold: poly-D,L-lactide (PDLLA) Electrospinning
Drug: docetaxel(DTX)/4T1 Cell Lines: breast cancer cells
Group 1: control group 
Group 2: Unloaded film, Group 3: DTX-loaded film
Group 4: Local subcutaneous injection of DTX 15mg/kg
Group 5: Intraperitoneal injection of DTX
Drug release duration: 24 days
Drug dosage released: Approximately 23.3%, 25.3% and 29.6% of DTX 
was released in 24 days from the 5, 10 and 20 wt% DTX/PDLLA 
scaffolds, respectively
Cytotoxicity against 4T1:
Group 1 and 2: No cytotoxicity
Group 3,4 and 5: cell growth inhibition rates of 20%, 34%, and 54%, respectively
Locoregional recurrence: Locally administrated DTX/PLA reduced locoregional recurrence after resection of the 
primary tumor 
Overall survival was improved in the DTX/PDLLA group compared with all the other groups
Electrospun DTX-loaded PDLLA nanofibers provide prolonged and sufficient 
cytotoxic drug locally, preventing local tumor recurrence post-surgically
8. Feng Chai/2014/France In vitro cell lines
Scaffold: cyclodextrin polymer (polyCD) functionalized 
hydroxyapatite (HA) admixing and sublimation
Drug: Gentamicin and cisplatin





Group 5: HA granules
Drug release duration: 48 hrs
Drug dosage released: in different media:
84, 82, and 74% respectively for Cis loaded scaffolds in human blood 
plasma, in 10% FBS enriched MEM and serum-free MEM
Cell Vitality against osteosarcoma cells: No difference (p>0.05) between polyCD-HA/dual and polyCD-HA/cis, both 
showed strong cytotoxic effect (20%±3%) to MG63 cells
HA, polyCD-HA and polyCD-HA/genta showed no toxic effect to MG63 cells with a similar level of cell vitality 
(95%±4%) to control group
Biodegradable polyCD functionalized HA material can load higher amounts of one 
or two selected drugs (antimitotic, antibiotic, etc.) which can be gradually 
released into tumor surroundings maintaining the therapeutic efficacy of drug
9. Vishal Gupta/2011/USA
In vitro cell lines and in 
vivo nude rats
Scaffold: Silk Fibroin(SF)- chitosan(CS) lyophilization
Drug: Emodin
Cell Lines: Breast cancer cell line GILM2
Group 1: SF only
Group 2: SF-CS blank scaffolds
Group 3: emodin-loaded SFCS scaffold
Drug release duration: 24 days
Drug dosage released: SF scaffolds showed highest emodin release as 
compared to all SFCS blends  However, there was no difference in 
release between various blends of different concentrations of SF and 
CS.
Cell Viability: SFCS scaffolds significantly decreased the number of viable cells as compared to cells in culture dishes 
(no SFCS, no emodin, p<0.01) and cells exposed to SFCS scaffolds only
In vivo response: emodin-loaded SFCS scaffold group showed decreased tumor presence and size
Cell Density: The cell density in remodeled SFCS scaffold (3238 ± 152 cells/mm2) was significantly higher (p<0.05) 
than the emodin loaded SFCS scaffold (2733 ± 118 cells/mm2).
Liposomal emodin-loaded 25:75 SFCS scaffold composites provide good 
mechanical integrity, optimal drug loading and release over time, and reduced 
breast cancer cell viability in vitro. Scaffolds were effective in reducing tumor 






In vitro cell lines and in-
vivo mouse model
Scaffold: poly(glycerol stearic acid-co-e-
caprolactone)PGC-C18/10, poly(glycerol-co-e-
caprolactone)PGC-OH adhered to collagen scaffolds 
(solution, evaporation and adhering)
Drug: hydroxycamptothecin HPCT
Cell Lines: Lewis lung carcinoma cells
Group 1: PGC-OH unloaded
Group 2: HCPT loaded PGC-OH
Group 3: Unloaded PGC-C18
Group 4: HCPT loaded PGC-C18
Drug release duration: 7 weeks/ 3 weeks 
Drug dosage released: PGC-C18 released in a more controlled manner 
than PGC-OH 
Cytotoxic Studies (in-vitro): HCPT loaded PGC-C18 films exhibited significant cytotoxicity for 7 weeks compared to 
unloaded PGC-C18
In vivo mouse studies: Local tumor growth was suppressed in loaded PGC-C18 compared with unloaded films and 
intravenous HPCT
HPCT loaded scaffolds help in controlled and sustained release of drug alongwith 





In vitro cell lines and In-
vivo mice model
Scaffold: human micro-fragmented adipose tissue 
(MFAT)
Drug: Paclitaxel(PTX)
Cell Lines: human Pancreatic Adenocarcinoma cell line, 
human Glioblastoma cell line U87MG and human, wild 
type and luciferase (Luc) transfected Neuroblastoma 
(NB) (IMR-32, SHSY5Y, HTLA-230, NB1691) cell lines/ 
orthotopic animal model of Neuroblastoma (NB)
Group 1: MFAT untreated
Group 2: MFAT-PTX
Group 3: Devitalised MFAT (DMFAT) untreated
Group 4: DMFAT-PTX
Group 5: Condition medium of MFAT-PTX and DMFAT-
PTX
Drug release duration: Total duration 60 days
Drug dosage released: after 1 day, the PTX released by DMFAT-PTX 
was double (p-EC= 124.8 ±15.59 ng/ml) compared to MFAT-PTX
The concentration of PTX derived from DMFAT-PTX was always higher 
than that released by MFATPTX
Anti-tumor activity: MFAT-PTX, DMFAT-PTX and condition media derived from both resulted in more than 90% of 
CFPAC-1 growth inhibition. Anticancer activity was also effective against IMR-32 and U87MG, (NB) and (GBM) cell 
lines
Anti-angiogenesis: MFAT-PTX, DMFAT-PTX and condition media derived from both are cytotoxic in all concentrations 
against Human Umbilical Vein ECs
In vivo: local administration of DMFAT-PTX at tumor site after its surgical resection blocked or delay NB relapse
Both MFAT and DMFAT work as natural biological scaffolds and help in efficiently 
killing cancer cells both in vito and in vivo by absorbing releasing significant 
amount of PTX
12. Qian Zhan/2013/China
In vitro cell lines and In 
vivo female mice
Scaffold: PGA-TMC and porcine gelatin (electrospinning)
Drug: Flofirinox
Cell Lines: Pancreatic Cancer cells
Group 1: Drug-eluting scaffold 
Group 2: Non-eluting scaffold
Group 3: Non-eluting scaffold/phosphate-buffered 
solution group in which the cell medium was 
supplemented with phosphate-buffered solution as a 
control
Drug release duration: for 3 weeks 
Drug dosage released: The release of FOLFIRINOX from scaffold could 
be attributed to the combined effect of physical disintegration and 
chemical decomposition/ 
MTT: Proliferation of pancreatic cancer cells on the drug-eluting scaffolds was arrested during the 3-week period of 
observation
Apoptosis assay: Apoptosis of the pancreatic cancer cell populations on the drug-eluting scaffolds escalated through 
week 3. However, no significant apoptosis was observed in cancer cell populations on either the non-eluting 
scaffolds or the tissue culture plates during the 3-week study period
In vivo tumor volume: 
Group 1: 302.24 ± 103.59 mm3 Group 2: 434.22 ± 132.98 mm2 Group 3: 951.78 ± 178.21 mm2 
The ability to destroy CD133+ and CXCR4+ cells in cancer tissue helped  
FOLFIRINOX loaded  scaffolds in stabilizing tumorigenesis and preventing hepatic 
metastasis 
Limitations: heterogeneous distribution of chemotherapeutic agents in fibers and 
shorter shelf-life of the scaffold
13. Ceren Kutlu/2014/Turkey In vitro cell lines
Scaffold: poly-lactic-co-glycolic acid (PLGA)-chitosan 
(emulsion–diffusion–evaporation)
Drug: 5-fluorouracil (5-FU) and bevacizumab
Cell Lines: Human Glioblastoma cell line T98G and 
Human Umbilical vein Endothelial Cells (HUVECs) 
Group 1: Chitosan blank scaffold 
Group 2: Chitosan scaffold loaded with 5-FU-PLGA 
nanoparticles
Group 3: bevacizumab loaded scaffold
Group 4: 5-FU- and bevacizumab-loaded scaffold
Drug release duration: 80 days Drug dosage released: Burst release 
was observed in the first 24h with release of 15% of encapsulated 5-
FU. 5-FU has continued in a controlled manner during the following 
days/
Cell Viability: 
Group 1 and Group 3: No effect
Group 2 and Group 4: Antiproliferative against T98G
Anti-angiogenesis: HUVECs are viable in the presence of blank and only bevacizumab-loaded scaffold. In group 2 
and 4, 5-FU prevented cell proliferation
Double effective chitosan scaffold containing anticancer and antiangiogenic agent 
inhibits tumor cells, T98G glioblastomas, by releasing 5-FU, and prevents 
proliferation of HUVECs, by releasing bevacizumab
14. Dong Gao/2017/China In vivo mice 
Scaffold: Purine-scaffold TLR7 agonist (GD5)
Drug: Doxirubicin
Cell Lines: EL4 T cell lymphoma cells injected in a mouse 
model
Group 1: Control
Group 2: DOX intratumoural
Group 3: GD5 intratumoural
Group 4: GD5 intraperitoneal
Group 5: Both GD5 and DOX intratumoural
Group 6: DOX intratumoural GD5 intraperitoneal
-----------
Survival Time: Mice treated with GD5 have more survival than control or DOX treated groups. 
Group 5 and 6 significantly improved survival compared with Group 3 and 4
Amongst group 5 and 6: Group 5 showed a notable increase in survival compared with group 6
Systemic antitumor effect: Either Co i.t. or Co i.p. group exhibited improved tumoricidal effectiveness compared 
with single-drug treatment groups
Anti-tumor Immunity in Long-term Surviving Mice:
EL4 tumor cells were significantly more sensitive to the effector cells from the drugs administration groups than Ctrl 
group; but no significant difference among GD5 i.t., GD5 i.p. and Co i.p. groups were observed. Only Co i.t. group 
and supra three groups have a significant difference
Combination therapy including TLR7 agonist GD5 and conventional drugs, like 
DOX can enhance antitumor effectiveness by generating strong cytokines and 
increasing immune response. This will help in eradicating both local and distant 
tumors enhancing local and systemic immune response
15.
Jacob H. Swet/2013/North 
Carolina
In-vivo rat model
Scaffold: Silica-calcium-phosphate nanocomposite 
(SCPC75) (solution and dried)
Drug: Cisplatin
Cell Lines: A rat model of Hepatocellular Carcinoma 
(HCC)
Group 1: Control Untreated
Group 2: Systemic Cisplatin (sCis)
Group 3: Blank SCPC75 placed adjacent to tumor (ADJ-
SCPC75)
Group 4: Cis-SCPC75 placed adjacent to tumor (ADJ-
SCPC75-Cis)
Group 5: Blank SCPC75 within tumor mass IT-SCPC75
Group 6: Cis-SCPC75 placed within tumor IT-SCPC75-Cis
Drug release duration: 14 days
Drug dosage released: In vivo SCPC75-Cis released 55% of the loaded 
cisplatin.
ADJ-SCPC75-Cis or IT-SCPC75-Cis compared with control show similar 
serum platinum concentration. 
sCis-treated animals showed  increased levels of platinum compared 
with all other groups
Platinum content in tumor tissue: IT-SCPC75-Cis showed significantly 
increased intratumoral platinum greater than other treatment groups
Tumor Growth: ADJ-SCPC75-Cis and IT-SCPC75-Cis demonstrated slower tumor growth compared with both control 
and sCis-treated animals
Histological analysis: No detectable necrosis in untreated, control tumors. Small areas of necrotic cell death were 
detected in animals receiving sCis
Significant areas of tissue necrosis were observed in tumors receiving ADJ-SCPC75-Cis or IT-SCPC75-Cis treatment
No significant difference was measured between the necrotic area in animals treated with ADJ-SCPC75-Cis and 
ITSCPC75-Cis
Loocal cisplatin delivery to the tumor mass using SCPC75 nano scaffold helps in 
overcoming the systemic toxicity of the drug which is associated with daily 
injection of cisplatin. This also increases the intratumoral drug delivery to inhibit 
the tumor growth
Conclusion:
Irrespective of the drugs, scaffold materials and assessment tools used, scaffold mediated 
localized delivery of chemotherapeutics is a potentially exciting method for drug delivery to 
solid tumours with the aim of preventing or minimising adverse systemic toxicity. However, 
scaffold placement and other variables discussed in this paper mean that the introduction of 
this potential method of chemotherapy is dependent on further research and appropriately 
designed, prospective clinical trials
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